Compare AUR & CYTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AUR | CYTK |
|---|---|---|
| Founded | 2017 | 1997 |
| Country | United States | United States |
| Employees | N/A | 673 |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.5B | 10.7B |
| IPO Year | 2021 | 2004 |
| Metric | AUR | CYTK |
|---|---|---|
| Price | $6.31 | $77.27 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 19 |
| Target Price | $9.43 | ★ $89.26 |
| AVG Volume (30 Days) | ★ 27.8M | 1.8M |
| Earning Date | 05-06-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 4.35 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $3,000,000.00 | ★ $13,368,000.00 |
| Revenue This Year | $407.30 | $7.37 |
| Revenue Next Year | $1,134.58 | $310.19 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $3.60 | $35.22 |
| 52 Week High | $8.57 | $88.31 |
| Indicator | AUR | CYTK |
|---|---|---|
| Relative Strength Index (RSI) | 44.55 | 48.34 |
| Support Level | $5.78 | $73.34 |
| Resistance Level | $6.75 | $79.66 |
| Average True Range (ATR) | 0.35 | 2.63 |
| MACD | -0.08 | 0.06 |
| Stochastic Oscillator | 24.06 | 49.86 |
Aurora Innovation is a US autonomous driving provider for heavy trucks. The company produces and sells its Aurora Driver system, which includes hardware installed in a vehicle, software to autonomously drive it, and data management to maintain and improve the software. Aurora targets long-haul routes. The company currently offers its trucking-as-a-service model, where it owns and operates the trucks and makes deliveries for customers. The company plans to start selling its driver-as-a-service model next year, where fleet owners will own the trucks and Aurora's software will operate them.
Cytokinetics Inc is a late-stage biopharmaceutical company focused on discovering, developing, and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary disease. The company's product, named as MYQORZO, is an allosteric and reversible inhibitor of cardiac myosin motor activity. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.